MEDP · Medpace Holdings, Inc.

$575.96 -2.34 (-0.40%)

Market Cap

$16.14B

27.91M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$2.53B +20%

FY2025

Net Income

$451.12M +11.6%

FY2025

Operating Margin

21.14% 0pp

FY2025

Diluted EPS

$15.28 +21%

FY2025

Operating Cash Flow

$713.22M +17.1%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Revenue	+20.1%	+22.3%	—	$2.81B – $2.89B	$2.78B	$2.53B^G	$2.11B^G	$1.89B	$1.46B	$1.14B	$925.93M	$860.97M	$704.59M	$436.15M	$421.58M
Selling, General & Administrative	+14.6%	+16.5%	—	—	$189.02M	$197.56M	$180.18M	$161.35M	$131.4M	$108.42M	$92.16M	$95.25M	$75.68M	$63.36M	$61.51M
Amortization of Intangibles	-34.4%	-34.5%	—	—	$783K	$946K	$1.44M	$2.2M	$3.35M	$5.11M	$7.88M	$14.83M	$29.56M	$37.9M	$50.67M
Total Costs & Expenses	+19.1%	+21.3%	—	—	$2.2B	$2B	$1.66B	$1.55B	$1.18B	$943.76M	$758.88M	$733.71M	$603.54M	$371.29M	$369.09M
Operating Income	+24.3%	+26.2%	—	—	$583.4M	$534.94M	$446.87M	$336.83M	$278.7M	$198.62M	$167.04M	$127.26M	$101.05M	$64.86M	$52.49M
Operating Margin	—	—	—	—	—	21.14%	21.19%	17.86%	19.09%	17.39%	18.04%	14.78%	14.34%	14.87%	12.45%
Other Non-Operating Income	+21.4%	+37.9%	—	—	$15.52M	$7.44M	$29.05M	-$1.14M	$4.16M	$3.24M	$1.49M	-$2.43M	-$7.1M	-$7.91M	-$30.53M
Pretax Income	+24.2%	+26.3%	—	—	$598.92M	$542.38M	$475.92M	$335.68M	$282.86M	$201.85M	$168.53M	$124.83M	$93.95M	$56.95M	$21.96M
Income Tax	+34.5%	+31.6%	—	—	$107.42M	$91.25M	$71.54M	$52.87M	$37.49M	$20M	$23.15M	$24.39M	$20.77M	$17.82M	$8.53M
Net Income	+22.5%	+25.4%	—	—	$491.5M	$451.12M	$404.39M	$282.81M	$245.37M	$181.85M	$145.38M	$100.44M	$73.19M	$39.12M	$13.43M
Net Margin	—	—	—	—	—	17.83%	19.17%	15%	16.81%	15.92%	15.7%	11.67%	10.39%	8.97%	3.18%
Net Income Available to Common Stockholders	+22.5%	+25.5%	—	—	—	$451.12M	$404.34M	$282.62M	$245.21M	$181.39M	$144.93M	$100.16M	$72.89M	$39.03M	$13.39M
Comprehensive Income	+24.7%	+25.5%	—	—	$490.07M	$460.96M	$399.72M	$285.13M	$237.82M	$177.13M	$147.99M	$100.22M	$71.4M	$42.13M	$12.24M
EPS (Basic) USD/shares	+27.4%	+30.9%	—	—	—	$15.64	$13.06	$9.20	$7.57	$5.06	$4.07	$2.79	$2.05	$1.00	$0.38
EPS (Diluted) USD/shares	+28.0%	+31.8%	—	$17.25 – $17.95	—	$15.28^G	$12.63^G	$8.88	$7.28	$4.81	$3.84	$2.67	$1.97	$0.98	$0.37
Shares Outstanding (Basic Avg) shares	-3.8%	-4.1%	—	—	—	28.85M	30.96M	30.72M	32.39M	35.86M	35.64M	35.88M	35.55M	39.06M	35.69M
Shares Outstanding (Diluted Avg) shares	-4.3%	-4.8%	—	—	—	29.53M	32.01M	31.84M	33.67M	37.7M	37.71M	37.58M	36.91M	39.84M	36.33M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2025: $2.4B in buybacks.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Peer median 4.46×

EV/EBIT

—

Peer median 27.90×

P/E (TTM)

33.94×

Peer median 34.36×

Peer medians compare against the 24 similar-size Diagnostics & Research companies (of 48 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022
Reportable Segment	$2,530,234,000	$2,109,054,000	$1,885,842,000	$1,459,996,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Oncology	$747,585,000	$651,237,000	$587,097,000	$467,796,000	$362,846,000	$297,675,000	$256,766,000	$189,056,000
Metabolic	$744,957,000	$457,542,000	$376,842,000	$244,682,000	$159,900,000	$126,075,000	$138,650,000	$124,837,000
Other	$408,548,000	$431,384,000	$404,844,000	$296,914,000	$267,415,000	$215,370,000	$196,159,000	$163,983,000
Central Nervous System	$254,838,000	$181,977,000	$160,057,000	$157,939,000	$121,548,000	$88,393,000	$91,746,000	$54,229,000
Cardiology	$239,371,000	$230,454,000	$193,690,000	$174,634,000	$119,692,000	$95,153,000	$91,258,000	$95,213,000
Antiviral and Anti-Infective	$134,935,000	$156,460,000	$163,312,000	$118,031,000	$110,976,000	$103,259,000	$86,390,000	$77,271,000
Direct Revenue	—	—	—	—	—	—	$0	$0
Reimbursed Out of Pocket Revenue	—	—	—	—	—	—	$0	$0

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022
Reportable Segment	$534,935,000	$446,870,000	$336,825,000	$278,697,000

Operating Margin by Segment (%)

Component	FY2025	FY2024	FY2023	FY2022
Reportable Segment	21.1%	21.2%	17.9%	19.1%

Key facts CIK 1668397 CUSIP 58506Q109 13F (30d) 226 filings 225 filers Visit website Investor relations